Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

NZ sharemarket rallies, ends day up 0.6%
Markets Market Close

NZ sharemarket rallies, ends day up 0.6%

The S&P/NZX 50 Index closed at 12,989.18, up 83.2 points or 0.64%.

Graham Skellern 14 Feb 2025
Toy entrepreneur quashes spec of NZME takeover
Finance

Toy entrepreneur quashes spec of NZME takeover

Zuru founder Nick Mowbray says a report speculating he could take over private media company NZME is wrong. On Friday morning, The Australian’s Data Room said “some wealthy Kiwis” were plotting to do something about the state of New Zealand’s media industry and cited Mowbray as a...

Victoria Young 14 Feb 2025
Below-normal rainfall sees NZ hydro storage drop to 91%
Markets

Below-normal rainfall sees NZ hydro storage drop to 91%

Last month was the second-driest January on record.

Staff reporters 14 Feb 2025
Gentailers' earnings: Don't look back in anger
Markets

Gentailers' earnings: Don't look back in anger

Reporting season will be about the winter past and the winter to come.

Ian Llewellyn 14 Feb 2025